Department of Medical and Surgical Sciences, University of Foggia, Foggia, Italy.
Section of Cardiology, Department of Clinical and Experimental Medicine, University of Messina, Policlinico G. Martino, Messina, Italy.
J Cardiovasc Electrophysiol. 2022 Aug;33(8):1874-1879. doi: 10.1111/jce.15596. Epub 2022 Jun 21.
Fever is a potential side effect of the Covid-19 vaccination. Patients with Brugada syndrome (BrS) have an increased risk of life-threatening arrhythmias when experiencing fever. Prompt treatment with antipyretic drugs is suggested in these patients.
To evaluate the incidence and management of fever within 48 h from Covid-19 vaccination among BrS patients.
One hundred sixty-three consecutive patients were enrolled in a prospective registry involving five European hospitals with a dedicated inherited disease ambulatory.
The mean age was 50 ± 14 years and 121 (75%) patients were male. Prevalence of Brugada electrocardiogram (ECG) pattern type-1, -2, and -3 was 32%, 44%, and 24%, respectively. Twenty-eight (17%) patients had an implantable cardioverter-defibrillator (ICD). Fever occurred in 32 (19%) BrS patients after 16 ± 10 h from vaccination, with a peak of body temperature of 37.9° ± 0.5°. Patients with fever were younger (39 ± 13 vs. 48 ± 13 years, p = .04). No additional differences in terms of sex and cardiovascular risk factors were found between patients with fever and not. Twenty-seven (84%) out of 32 patients experienced mild fever and five (16%) moderate fever. Pharmacological treatment with antipyretic drugs was required in 18 (56%) out of 32 patients and was associated with the resolution of symptoms. No patient required hospital admission and no arrhythmic episode was recorded in patients with ICD within 48 h after vaccination. No induced type 1 BrS ECG pattern and new ECG features were found among patients with moderate fever.
Fever is a common side effect in BrS patients after the Covid-19 vaccination. Careful evaluation of body temperature and prompt treatment with antipyretic drugs may be needed.
发热是新冠疫苗接种的潜在副作用。患有布鲁加达综合征（BrS）的患者在发热时发生危及生命的心律失常的风险增加。建议这些患者及时使用退热药物进行治疗。
评估 BrS 患者接种新冠疫苗后 48 小时内发热的发生率和处理方法。
连续纳入了五个欧洲医院的五个欧洲医院的 163 例连续患者，这些医院均设有专门的遗传性疾病门诊。
患者平均年龄为 50±14 岁，121 例（75%）为男性。1 型、2 型和 3 型 Brugada 心电图（ECG）模式的发生率分别为 32%、44%和 24%。28 例（17%）患者植入了植入式心律转复除颤器（ICD）。接种疫苗后 16±10 小时，32 例（19%）BrS 患者出现发热，体温峰值为 37.9°±0.5°。发热患者年龄更小（39±13 岁 vs. 48±13 岁，p=0.04）。未发现发热患者与无发热患者在性别和心血管危险因素方面存在差异。32 例患者中 27 例（84%）为轻度发热，5 例（16%）为中度发热。32 例患者中有 18 例（56%）需要使用退热药物进行药物治疗，症状随之缓解。没有患者需要住院治疗，接种疫苗后 48 小时内植入 ICD 的患者也未发生心律失常事件。中度发热患者中未发现诱导 1 型 BrS ECG 模式和新的 ECG 特征。
发热是 BrS 患者接种新冠疫苗后的常见副作用。可能需要仔细评估体温并及时使用退热药物进行治疗。
